GSK said on Monday that it has entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China, News.Az reports, citing Reuters.
Under the agreement, which marks GSK’s second deal with a Chinese pharmaceutical group following a $500 million partnership with Jiangsu Hengrui to develop up to a dozen new medicines, Sino’s unit Chia Tai Tianqing Pharmaceutical (CTTQ) will purchase bepirovirsen from GSK for an initial period of five and a half years.
The agreement may be extended further by mutual consent of both parties.
Bepirovirsen is GSK’s experimental therapy aimed at treating hepatitis B through a multi-pronged approach.
It is designed to block viral DNA replication, reduce hepatitis B surface antigen levels in the blood, and enhance the body’s immune response, with the goal of achieving longer-term control of the disease.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。